EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial

Robab Ebrahimi Barogh, Seyed Ali Jeddi, Ghasem Rahmatpour Rokni, Hossein Mohammad Taghi Fam, Abbas Raeisabadi, Zahra Yahyazadeh, Seyyed Mobin Rahimnia iD, Pedram Ebrahimnejad, Eisa Nazar iD, Nasim Gholizadeh iD, Iman Haghani iD, Mohsen Nosratabadi iD und 7 weitere

Mycoses · 2026-06 · 69 (6)

DOI: 10.1111/myc.70196 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Mycoses, online erschienen am 08.06.2026. Verfasst von Robab Ebrahimi Barogh und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Immunology, Parasitology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran. Hauptthemen laut MEDLINE: Antifungal Agents, Imidazoles, Nanostructures, Tinea. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Invasive Fungi Research Center, Mazandaran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dermatophytosis is a common superficial fungal infection that is increasingly complicated by terbinafine (TRB)‐resistant strains, especially Trichophyton indotineae . Conventional antifungals often show limited efficacy against resistant isolates, highlighting the need for novel treatments. This study evaluated the efficacy and safety of nanostructured lipid carrier–loaded luliconazole (NLC‐LCZ) gel in TRB‐resistant dermatophytosis. Materials and Methods In a randomized, clinical trial conducted at Touba Specialty Clinic, Sari, Iran, forty‐eight adults with confirmed TRB‐resistant dermatophytosis were assigned to oral itraconazole (ITZ), topical luliconazole, NLC‐LCZ gel, or ITZ + NLC‐LCZ gel for 4 weeks ( n = 12 each). The primary endpoint was complete recovery (clinical and mycological), while secondary endpoints included lesion size, itch, inflammation, Dermatology Life Quality Index (DLQI), and safety.

Results

Complete recovery occurred in 83.3% of ITZ + NLC‐LCZ, 75% of NLC‐LCZ, 58.3% of LCZ, and 0% of ITZ alone. LCZ and NLC‐LCZ had lower MIC 50 / MIC 90 values (0.016 μg/mL) compared with ITZ (MIC 90 : 8 μg/mL) and TRB (MIC 90 : 4 μg/mL). DLQI improved most in NLC‐LCZ (score: 2) and ITZ + NLC‐LCZ (score: 3) groups ( p < 0.001). Adverse events were mild and did not require discontinuation.

Conclusions

These findings indicate that NLC‐LCZ enhanced antifungal efficacy and quality of life in TRB‐resistant dermatophytosis, and that combination therapy with ITZ + NLC‐LCZ yielded the highest recovery, representing a promising strategy against resistant infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsImidazolesNanostructuresTineaDrug CarriersHumansAdultMaleFemaleDrug Resistance, FungalMiddle AgedTreatment OutcomeIranLipidsYoung AdultItraconazoleMicrobial Sensitivity TestsTrichophytonAdministration, TopicalAgedTerbinafineQuality of Life

Stichwörter der Autor:innen

trichophyton indotineaeantifungal resistanceclinical trialdermatophytosisluliconazolenanostructured lipid carriers

Substanzen

Antifungal AgentsImidazolesluliconazoleLipidsDrug CarriersItraconazoleTerbinafine

Autor:innen und Institutionen

  • Department of Medical Microbiology, Immunology, Parasitology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
  • Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Pharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

ORCID-Profile: Seyyed Mobin Rahimnia, Eisa Nazar, Nasim Gholizadeh, Iman Haghani, Mohsen Nosratabadi, Armaghan Kazeminejad, Javad Javidnia, Mohammad Taghi Hedayati, Jacques F Meis, Ahmed Al-Harrasi, Mahdi Abastabar

Förderung

  • Invasive Fungi Research Center, Mazandaran University of Medical Sciences

Zitieren

APA

Barogh, R. E., Jeddi, S. A., Rokni, G. R., Fam, H. M. T., Raeisabadi, A., Yahyazadeh, Z., Rahimnia, S. M., Ebrahimnejad, P., Nazar, E., Gholizadeh, N., Haghani, I., Nosratabadi, M., Kazeminejad, A., Javidnia, J., Hedayati, M. T., Meis, J. F., Al-Harrasi, A., Abastabar, M., & Al-Hatmi, A. M. S. (2026). Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial. Mycoses, 69(6). https://doi.org/10.1111/myc.70196

Vancouver

Barogh RE, Jeddi SA, Rokni GR, Fam HMT, Raeisabadi A, Yahyazadeh Z, et al. Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial. Mycoses. 2026;69(6). doi:10.1111/myc.70196

BibTeX
@article{Barogh2026,
  author = {Barogh, Robab Ebrahimi and Jeddi, Seyed Ali and Rokni, Ghasem Rahmatpour and Fam, Hossein Mohammad Taghi and Raeisabadi, Abbas and Yahyazadeh, Zahra and Rahimnia, Seyyed Mobin and Ebrahimnejad, Pedram and Nazar, Eisa and Gholizadeh, Nasim and Haghani, Iman and Nosratabadi, Mohsen and Kazeminejad, Armaghan and Javidnia, Javad and Hedayati, Mohammad Taghi and Meis, Jacques F and Al-Harrasi, Ahmed and Abastabar, Mahdi and Al-Hatmi, Abdullah M S},
  title = {Efficacy Evaluation of Luliconazole‐Loaded Nanostructured Lipid Carriers in Treatment‐Resistant Dermatophytosis: A Randomized Clinical Trial},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {6},
  doi = {10.1111/myc.70196}
}
Kostenlos starten →